Teriparatide Cinnagen: Withdrawal of the marketing authorisation application



CinnaGen Co. Unipessoal Lda withdrew its application for a marketing authorisation of Teriparatide Cinnagen for the treatment of osteoporosis in adults.

The company withdrew the application on 9 September 2021.

Key facts

Teriparatide Cinnagen
Product number
International non-proprietary name (INN) or common name
  • teriparatide
Active substance
  • teriparatide
Date of withdrawal
Company making the application
CinnaGen Co, Unipessoal LDA
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating
1 rating